Abstract
The identification of activating mutations in the tyrosine kinase domain of the EGF receptor (EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic revolution in the treatment of patients with metastatic non-small-cell lung cancer (NSCLC). To date, eight randomized clinical trials have demonstrated that first-line treatment with TKIs in advanced NSCLC patients harboring activating EGFR mutations is associated with significant improvement in response rate, progression-free survival, quality of life and tolerability, compared with platinum-based chemotherapy. These results prompted the EGFR TKIs as the current standard first-line treatment of patients with advanced NSCLC harboring activating EGFR mutations. However, there are several questions that need to be addressed, including the best choice among different EGFR TKIs, the treatment of resistant disease and of patients with specific clinical conditions. Ongoing and future, well-designed trials should answer all these questions.
| Original language | English |
|---|---|
| Pages (from-to) | 1207-1218 |
| Number of pages | 12 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 13 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2013 |
Fingerprint
Keywords
- afatinib
- clinical trials
- dacomitinib
- EGFR
- erlotinib
- gefitinib
- neratinib
- NSCLC
ASJC Scopus subject areas
- Pharmacology (medical)
- Oncology
Cite this
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations : Current evidence and future perspectives. / Costanzo, Raffaele; Montanino, Agnese; Di Maio, Massimo; Piccirillo, Maria Carmela; Sandomenico, Claudia; Giordano, Pasqualina; Daniele, Gennaro; Franco, Renato; Perrone, Francesco; Rocco, Gaetano; Normanno, Nicola; Morabito, Alessandro.
In: Expert Review of Anticancer Therapy, Vol. 13, No. 10, 2013, p. 1207-1218.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations
T2 - Current evidence and future perspectives
AU - Costanzo, Raffaele
AU - Montanino, Agnese
AU - Di Maio, Massimo
AU - Piccirillo, Maria Carmela
AU - Sandomenico, Claudia
AU - Giordano, Pasqualina
AU - Daniele, Gennaro
AU - Franco, Renato
AU - Perrone, Francesco
AU - Rocco, Gaetano
AU - Normanno, Nicola
AU - Morabito, Alessandro
PY - 2013
Y1 - 2013
N2 - The identification of activating mutations in the tyrosine kinase domain of the EGF receptor (EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic revolution in the treatment of patients with metastatic non-small-cell lung cancer (NSCLC). To date, eight randomized clinical trials have demonstrated that first-line treatment with TKIs in advanced NSCLC patients harboring activating EGFR mutations is associated with significant improvement in response rate, progression-free survival, quality of life and tolerability, compared with platinum-based chemotherapy. These results prompted the EGFR TKIs as the current standard first-line treatment of patients with advanced NSCLC harboring activating EGFR mutations. However, there are several questions that need to be addressed, including the best choice among different EGFR TKIs, the treatment of resistant disease and of patients with specific clinical conditions. Ongoing and future, well-designed trials should answer all these questions.
AB - The identification of activating mutations in the tyrosine kinase domain of the EGF receptor (EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic revolution in the treatment of patients with metastatic non-small-cell lung cancer (NSCLC). To date, eight randomized clinical trials have demonstrated that first-line treatment with TKIs in advanced NSCLC patients harboring activating EGFR mutations is associated with significant improvement in response rate, progression-free survival, quality of life and tolerability, compared with platinum-based chemotherapy. These results prompted the EGFR TKIs as the current standard first-line treatment of patients with advanced NSCLC harboring activating EGFR mutations. However, there are several questions that need to be addressed, including the best choice among different EGFR TKIs, the treatment of resistant disease and of patients with specific clinical conditions. Ongoing and future, well-designed trials should answer all these questions.
KW - afatinib
KW - clinical trials
KW - dacomitinib
KW - EGFR
KW - erlotinib
KW - gefitinib
KW - neratinib
KW - NSCLC
UR - http://www.scopus.com/inward/record.url?scp=84886390038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886390038&partnerID=8YFLogxK
U2 - 10.1586/14737140.2013.845092
DO - 10.1586/14737140.2013.845092
M3 - Article
C2 - 24134422
AN - SCOPUS:84886390038
VL - 13
SP - 1207
EP - 1218
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 10
ER -